HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | Gag(180-188) | Gag Epitope Map
View variants at this location |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
TPQDLNTML
|
Epitope Alignment | ||||||||||
| Variants |
|
|||||||||||
| Epitope Name | Gag-TL9 | |||||||||||
| Species (MHC/HLA) | human(B*42:01) | |||||||||||
Showing all: 3 variant(s).
| Variant ID. | 4252 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPtDLNTML |
| Mutations | Q/T |
| Epitope Location | Q3T |
| HXB2 Location | Q182T |
| Mutation Type | LE: literature escape |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Other |
| Note | TPtDLNTML (Q182T) is documented escape variant. It was observed to arise in B*42+ (which is a restricting HLA for TL9) subject 133-M when her B*42- child, 133-C, was at age 7. Q182T was also observed in B*42+ subject 517-M when her B*42+ child, 517-C, was 0.25yrs old. However, it was not observed in 517-C. In B*42+ subject 021-M, the Q182T variant was observed starting at 0.1yr before the birth of her child, 021-C. However it was not observed 021-C, who is B*42+, until 4.9yrs. |
| Variant ID. | 4253 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPaDLNTML |
| Mutations | Q/A |
| Epitope Location | Q3A |
| HXB2 Location | Q182A |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Other |
| Note | TPaDLNTML (Q182A) was observed in B*42+ (which is a restricting HLA for TL9) subject 517-M when her B*42+ child, 517-C, was 0.25yrs old. However, it was not observed in 517-C. |
| Variant ID. | 4349 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPsDLNTML |
| Mutations | Q/S |
| Epitope Location | Q3S |
| HXB2 Location | Q182S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Other |
| Note | TPsDLNTML (Q182S) was observed in B*8101+ (which is a restricting HLA for TL9) subject K-3046-C at age 7.8. K-3046-C was a subject in the Pediatric Early HAART and Strategic Treatment Interruption Study. |
Leitman2017 Ellen M. Leitman, Christina F. Thobakgale, Emily Adland, M. Azim Ansari, Jayna Raghwani, Andrew J. Prendergast, Gareth Tudor-Williams, Photini Kiepiela, Joris Hemelaar, Jacqui Brener, Ming-Han Tsai, Masahiko Mori, Lynn Riddell, Graz Luzzi, Pieter Jooste, Thumbi Ndung'u, Bruce D. Walker, Oliver G. Pybus, Paul Kellam, Vivek Naranbhai, Philippa C. Matthews, Astrid Gall, and Philip J. R. Goulder. Role of HIV-Specific CD8+ T Cells in Pediatric HIV Cure Strategies after Widespread Early Viral Escape. J. Exp. Med., 214(11):3239-3261, 6 Nov 2017. PubMed ID: 28983013. Show all entries for this paper.